# US 12,427,189 B2 · Vaccine comprising epitope of heat shock protein, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,427,189 B2
- Document ID: US12427189B2
- Status: Granted
- Kind: B2
- Application number: 17/885,255
- Filed: 2022-08-10
- Published: 2023-03-16
- Granted: 2025-09-30
- Earliest claimed: 2018-02-19
- Assignees: Aston Sci. Co., Ltd.
- Applicants: Aston Sci. Co., Ltd.
- Inventors: Kyong Hwa Park; Jinho Kang
- Web page: https://patentgrep.com/patent/US12427189B2

## CPC

- A61K 39/001176: {Heat shock proteins}
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61P 35/00: Antineoplastic agents
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/47: from mammals
- C07K 16/18: against material from animals or humans
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/575: {humoral response}
- A61K 2039/70: {Multivalent vaccine}
- A61K 2039/812: {Breast}
- C07K 16/2818: {against CD28 or CD152}
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A vaccine containing an epitope of a heat shock protein 90 and uses thereof are disclosed. The epitope(s) of heat shock protein 90 has the amino acid sequence of SEQ ID NO: 1 and/or 2. A multi-epitope vaccine containing the epitope(s) and a method for treating or preventing cancer using the same are disclosed.

## Claims

### Claim 1

A method for treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a composition, wherein the composition comprises a mixture of two different MHC class II-specific epitopes from a heat shock protein 90 (HSP90), wherein the two MHC class II-specific epitopes consist of the amino acid sequence of SEQ ID NO: 1 and the amino acid sequence of SEQ ID NO: 2, wherein the composition further comprises an anticancer adjuvant.

### Claim 2 (depends on 1)

The method for treating cancer according to claim 1, wherein the composition induces production of an antibody and/or activation of immune cells that recognizes heat shock protein 90 as an antigen.

### Claim 3 (depends on 1)

The method for treating cancer according to claim 1, wherein the composition further comprises STING (Stimulator of Interferon gene) agonist.

### Claim 4 (depends on 1)

The method for treating cancer according to claim 1, wherein the composition further comprises an immune checkpoint inhibitor against any one selected from the group consisting of CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), PD-1 (Programmed cell death protein 1), LAG-3 (Lymphocyte Activation Gene-3), TIM-3 (T-cell Immunoglobulin and Mucin-domain containing-3), TIGIT (T-cell Immunoreceptor with IG and ITIM domain), and VISTA (V-domain Ig Suppressor of T cell Activation).

### Claim 5 (depends on 1)

The method for treating cancer according to claim 1, wherein the cancer is selected from the group consisting of squamous cell cancer, small cell lung cancer, non-small cell lung cancer, lung cancer, peritoneal cancer, colon cancer, biliary tract tumor, nasopharyngeal cancer, laryngeal cancer, bronchial cancer, oral cancer, osteosarcoma, gallbladder cancer, kidney cancer, leukemia, bladder cancer, melanoma, brain cancer, glioma, brain tumor, skin cancer, pancreatic cancer, breast cancer, liver cancer, bone marrow cancer, esophageal cancer, colon cancer, stomach cancer, cervical cancer, prostate cancer, ovarian cancer, head and neck cancer, rectal cancer, and a combination thereof.

### Claim 6 (depends on 1)

A method for treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a composition, wherein the composition comprise nucleic acid molecules encoding the two MHC class II-specific epitopes, as described in claim 1, wherein the composition further comprises an anticancer adjuvant.

### Claim 7

A method for treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a composition, wherein the composition comprises an isolated heat shock protein 90 (HSP90)-specific MHC class II epitope, wherein the epitope consists of a peptide selected from the group consisting of SEQ ID NOs: 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14, wherein the composition further comprises an anticancer adjuvant.

### Claim 8 (depends on 7)

The method for treating cancer according to claim 7, wherein the composition induces production of an antibody and/or activation of immune cells that recognizes heat shock protein 90 as an antigen.

### Claim 9 (depends on 7)

The method for treating cancer according to claim 7, wherein the composition further comprises an anticancer adjuvant.

### Claim 10 (depends on 7)

The method for treating cancer according to claim 7, wherein the composition further comprises STING (Stimulator of Interferon gene) agonist.

### Claim 11 (depends on 7)

The method for treating cancer according to claim 7, wherein the composition further comprises an immune checkpoint inhibitor against any one selected from the group consisting of CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), PD-1 (Programmed cell death protein 1), LAG-3 (Lymphocyte Activation Gene-3), TIM-3 (T-cell Immunoglobulin and Mucin-domain containing-3), TIGIT (T-cell Immunoreceptor with IG and ITIM domain), and VISTA (V-domain Ig Suppressor of T cell Activation).

### Claim 12 (depends on 7)

The method for treating cancer according to claim 7, wherein the cancer is selected from the group consisting of squamous cell cancer, small cell lung cancer, non-small cell lung cancer, lung cancer, peritoneal cancer, colon cancer, biliary tract tumor, nasopharyngeal cancer, laryngeal cancer, bronchial cancer, oral cancer, osteosarcoma, gallbladder cancer, kidney cancer, leukemia, bladder cancer, melanoma, brain cancer, glioma, brain tumor, skin cancer, pancreatic cancer, breast cancer, liver cancer, bone marrow cancer, esophageal cancer, colon cancer, stomach cancer, cervical cancer, prostate cancer, ovarian cancer, head and neck cancer, rectal cancer, and a combination thereof.

### Claim 13

A method for treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a composition, wherein the composition comprises nucleic acid molecule encoding an epitope consisting of a peptide selected from the group consisting of SEQ ID NOs: 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14, wherein the composition further comprises an anticancer adjuvant.